National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria

AstraZeneca897 enrolled

Overview

National, prospective, multicentric, non-interventional registry-based study, conducted among oncologists, pulmonologists in community and university hospitals, from the public sector in Algeria. The study will collect information on the characteristics, and lung carcinomas patterns of patients whose lung cancer diagnosis was confirmed by a pathologist during the study period.

The study consists of: * All patients meeting inclusion/exclusion criteria presenting to their oncologists/pulmonologists for a routine visit during recruitment period will be sequentially asked to participate to the study. * The patients who do not consent will only be reported as new case of lung cancer for the incidence study. The patients who consent to participate to the study will perform four in-hospital visits (Inclusion visit, visit at 3, 6 and 12 months). In addition to the 4 visits, a phone contact with the patients every 6 months at years 2,3, 4 and 5 will be done by the investigator or one of his/her authorised representative or the CRO or during a routine visit to the investigator, to check the patient's survival status. THE STUDY DURATION 72 MONTHS

Study Type

OBSERVATIONAL

Enrollment

897

Conditions

Oncology & Epidemiology & Lung Cancer

Interventions

NIS observational studOTHER

NIS observational study : Epidemiologic registry

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist * Aged at least18 years at diagnosis * Patients who provide their informed consent form Exclusion Criteria: * Patients who did not provide the informed consent form * Patients with a mental or psychological disorder according to their treating clinicians

Locations (3)

Research Site

Algiers, Algeria

Research Site

Constantine, Algeria

Research Site

Oran, Algeria

Outcomes

Primary Outcomes

incidence of lung cancer

incidence of lung cancer, all types, stages and ages combined, in men and women newly diagnosed with lung cancer in Algeria over 12 months of recruitment period

Time frame: 12 months of recruitment period

Secondary Outcomes

incidence of newly diagnosed lung cancer

1\) To characterise the incidence of newly diagnosed lung cancer in Algeria in a 12 month period according to patient and disease characteristics (Wilaya, sex, age, lung cancer type, stage disease and smoking status).

Time frame: 12 month period

survival

Time frame: at 12, 24, 36, 48 and 60 months of follow-up.

quality of life -EORTC QLQ-C30

To evaluate the quality of life of patients diagnosed with lung cancer in Algeria according to EORTC QLQ-C30 )

Time frame: baseline, 3, 6 and 12 months follow-up.

Quality Of Life-EORTC QLQ- LC13

To evaluate the quality of life of patients diagnosed with lung cancer in Algeria according to EORTC QLQ- LC13

Time frame: baseline, 3, 6 and 12 months follow-up.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.